AbbVie Data Underscores Immunology Growth Potential With SKYRIZI And RINVOQ
AbbVie (NYSE:ABBV) presented new long term clinical and real world data for its gastroenterology portfolio at the 2026 Digestive Disease Week. The data highlighted SKYRIZI and RINVOQ in Crohn's disease and ulcerative colitis, with reports of sustained patient benefits and strong real world performance. These findings relate to AbbVie's efforts to address unmet clinical needs and reinforce its position in inflammatory bowel disease treatments. AbbVie is a large biopharmaceutical company with...
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.